Domperidone Expanded Access Treatment Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To allow the use of domperidone by patients with gastrointestinal disorders who have failed standard therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms

NCT03810287

Gastroparesis

NO_LONGER_AVAILABLE

Domperidone for Chronic Nausea and Vomiting

NCT02757534

Gastroparesis

NO_LONGER_AVAILABLE

Domperidone in Treating Patients With Gastrointestinal Disorders

NCT01696734

Digestive System Disorder Dyspepsia Esophagitis +4 more

RECRUITING PHASE3

Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

NCT01711918

Patients With Gastroparesis Who Have Failed Standard Therapy

COMPLETED NA

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

NCT05832151

Diabetic Gastroparesis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To provide oral domperidone to patients ≥12 years of age where, according to the investigator's judgment, a prokinetic effect is needed for the relief of refractory gastroesophageal reflux disease with upper gastrointestinal (GI) symptoms, gastroparesis, and chronic constipation in patients whom the potential benefit may outweigh the risk of cardiovascular adverse reactions including QT prolongation, Torsades de Pointes, and death.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroparesis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Domperidone Oral Product

10-30 mg of oral domperidone administered QID.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female
2. Age 12 and older
3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events

Exclusion Criteria

History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsades de Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.

1. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc \> 450 milliseconds for males, QTc\>470 milliseconds for females).
2. Hepatic dysfunction
3. Renal insufficiency
4. Clinically significant electrolyte disorders.
5. Gastrointestinal hemorrhage or obstruction
6. Presence of a prolactinoma (prolactin-releasing pituitary tumor).
7. Pregnant or breast feeding female
8. Known allergy to domperidone

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No